glutathione transport system γ-Glutamyl Cycle Protein Metabolism
Description
doi: 10.3390/ph17040497 95 GaoQLiGZuYXuYWangCXiangDet al
A doctor will only administer it if the potential benefits outweigh the risks.
Trastuzumab deruxtecan (T-DXd), which conjugates a topoisomerase I inhibitor to the trastuzumab scaffold, demonstrates high efficacy across HER2-expressing breast, gastric, and gynaecologic tumours
This enzymatic defect reduces synthesis of glutathione and the resulting low intracellular glutathione levels remove the normal tonic inhibition of the enzyme -glutamylcysteine synthetase (Figure 1 and Figure 2, reaction 4)
